Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Oklahoma for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Oklahoma only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Oklahoma (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Melinda Dunlap (NPI 1609096668)

Field	Value
Entity Type	Individual
Organization	Melinda Dunlap
Address	12697 E 51st St
City	Tulsa
State	OK
ZIP	74146
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	May 1, 2007

Payer Source	Total Paid
Medicare	$2.1M
Medicaid	$0

Key Findings

Provider tenure and payer footprint: MELINDA DUNLAP has an NPI enumerated on 2007-05-01 (~19 years ago) and reports $2.1M in lifetime Medicare revenue while reporting none in Medicaid (no Medicaid billing on file). This makes the provider effectively single-payer (Medicare) in the available claims data and indicates a long-established Medicare billing history.

Revenue concentration in Medicare: the top three Medicare codes (J9271, J9299, J9144) account for 56.2% of this provider's total Medicare revenue, with those codes contributing $537.5K, $321.1K, and $232.6K respectively. These three codes are the primary revenue drivers and reflect a concentrated exposure to high-cost oncology injectables.

Service-line profile: the dominant codes J9271 (pembrolizumab), J9299 (nivolumab) and J9144 (daratumumab) — together with chemotherapy administration 96413 ($40.3K) and office E/M 99214 ($78.4K) — are consistent with a hematology/oncology infusion practice that delivers checkpoint inhibitors, monoclonal antibodies, and chemotherapy in the outpatient setting. The presence of PET/CT codes 78815 ($91K) and 78816 ($19.6K) further supports routine use of diagnostic imaging commonly associated with oncology care.

Competitive standing for lead therapeutics: for her top single-agent revenue driver J9271 she ranks #902 of 1841 (51th percentile; typical, unremarkable volume for this code), for J9299 she ranks #286 of 505 (43th percentile; typical, unremarkable volume for this code), and for J9144 she ranks #421 of 615 (30th percentile; typical, unremarkable volume for this code). These rank/percentile positions indicate a modest national presence on these agents rather than dominance among peers.

High ambulatory visit and selected lab volumes: 99214 is reported at 891 claims and $78.4K revenue and is characterized as "notably above typical national volume for this code" (97th percentile), showing relatively high office-based management volume. Related lab codes 80053 ($14.2K) and 85025 ($11.8K) rank in the 96th percentile and are described in the data as typical, unremarkable volume for those codes, which together imply steady on-site ordering of routine labs alongside office visits.

Biosimilar and supportive-care mix: the provider bills multiple biosimilar product codes — Q5118 (bevacizumab-bvzr, $42.6K), Q5116 (trastuzumab-qyyp, $36.8K), Q5119 (rituximab-pvvr, $24.2K), Q5122 (pegfilgrastim-apgf, $20.4K) and Q5106 (epoetin alfa-epbx, $13.1K) — indicating routine use of biosimilar agents and supportive-care biologics in treatment regimens. This pattern suggests formulary or cost-management behaviors common in oncology infusion practices that mix originator and biosimilar products.

Imaging and advanced therapy utilization: imaging-related entries such as 78815 ($91K; 65th percentile, typical) and A9552 ($13.1K; 71th percentile, typical) alongside radiation delivery code G6015 ($27.6K; 16th percentile, typical) show that PET/CT imaging and occasional advanced radiation delivery are part of the billed services. These codes point to access to diagnostic imaging integral to oncology staging and some utilization of modality-specific therapy sessions.

Single-payer operational implication: with $2.1M recorded from Medicare and no Medicaid billing on file, the provider’s revenue mix is concentrated in Medicare beneficiaries and Medicare-covered oncology drugs and services. For payer/provider analysts, this suggests contract and utilization reviews should focus on Medicare reimbursement patterns, oncology drug acquisition costs, and infusion suite throughput rather than Medicaid program dynamics.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

93 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	12,500	$40	$537.5K
J9299	Injection, nivolumab, 1 mg	13,380	$20	$321.1K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	6,120	$40	$232.6K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	90	$1,020	$91K
J1930	Injection, lanreotide, 1 mg	1,920	$50	$86.4K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	3,170	$30	$82.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	890	$90	$78.4K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	1,900	$40	$68.4K
J3490	Unclassified drugs	110	$480	$54.7K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	1,640	$30	$42.6K

Showing 1–10 of 93

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 93 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Oklahoma Distribution

Melinda Dunlap — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Oklahoma

Full comparison — all codes billed, vs. state median

93 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	3	10	10,600	$40	$466.9K
J9299	5	10	14,050	$20	$324.4K
J9144	5	10	6,480	$40	$248.5K
G6015	10	10	270	$250	$141K
J1930	6	10	2,910	$40	$137.2K
J1569	11	20	3,670	$30	$125.8K
J0897	35	70	2,130	$20	$91.2K
J1449	4	10	3,040	$30	$78.5K
Q5118	2	10	1,480	$30	$37.8K
Q5119	4	10	1,280	$20	$31.1K

Showing 1–10 of 93

Related Providers

Other providers that share a Tax Identification Number (TIN) with Melinda Dunlap, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Grenville Jones	ME	Therapeutic Radiology Physician	$2.8M	$0
Scott Cole	OK	Hematology & Oncology Physician	$2.3M	$0
Charles Taylor	OK	Hematology & Oncology Physician	$2.3M	$0
Mark Olsen	OK	Hematology & Oncology Physician	$2.2M	$0
Paul Zito	OK	Hematology & Oncology Physician	$2.2M	$0
Mark Jennings	TX	Internal Medicine Physician	$2.1M	$0
Oklahoma Cancer Specialists And Research Institute LLC	OK	Hematology & Oncology Physician	$0	$1.7M
Ali Moussa	OK	Hematology & Oncology Physician	$1.6M	$0
Caleb Scheckel	OK	Hematology & Oncology Physician	$1.6M	$0
Leslie Yonemoto	OK	Radiation Oncology Physician	$1.4M	$0

Nearby Providers

Other providers in the same ZIP code as Melinda Dunlap, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Option 1 Nutrition Solutions LLC	OK	Durable Medical Equipment & Medical Supplies	$0	$18.8M
Regional Medical Laboratory, Inc	OK	Clinical Medical Laboratory	$0	$17.6M
Labcorp Oklahoma, Inc.	OK	Clinical Medical Laboratory	$6.8M	$7.8M
Access Pain Solutions	OK	Pain Medicine Physician	$0	$13.1M
Osu Center For Health Sciences	OK	Medical Specialty Clinic/Center	$0	$10.5M
Advanced Pediatric Care	OK	Durable Medical Equipment & Medical Supplies	$0	$4.9M
Asm LLC	OK	Customized Equipment (DME)	$0	$4.7M
Pathology Laboratory Associates, Inc.	OK	Anatomic Pathology & Clinical Pathology Physician	$22.2K	$3.9M
Sleep Management, L.L.C.	OK	Oxygen Equipment & Supplies (DME)	$0	$3.6M
Tulsa Bone & Joint Associates PC	OK	Orthopaedic Surgery Physician	$0	$3M

Melinda Dunlap — Billing Profile & Reimbursement Data

Sign up for Melinda Dunlap — Billing Profile & Reimbursement Data policy alerts

Melinda Dunlap — Billing Profile & Reimbursement Data

Sign up for Melinda Dunlap — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References